product summary
company name :
Cell Signaling Technology
product type :
antibody
product name :
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb (Alexa Fluor® 488 Conjugate)
catalog :
2846
clonality :
monoclonal
host :
rabbit
conjugate :
AF488
antigen modification :
phosphorylated
clone name :
236B4
reactivity :
human, mouse, rat
application :
flow cytometry
more info or order :
Cell Signaling Technology product webpage
citations: 21
Published Application/Species/Sample/DilutionReference
  • flow cytometry; mouse; fig 9
Pei B, Zhao M, Miller B, Véla J, Bruinsma M, Virgin H, et al. Invariant NKT cells require autophagy to coordinate proliferation and survival signals during differentiation. J Immunol. 2015;194:5872-84 pubmed publisher
  • flow cytometry; mouse
Zhang Y, Wu B, Metelli A, Thaxton J, Hong F, Rachidi S, et al. GP96 is a GARP chaperone and controls regulatory T cell functions. J Clin Invest. 2015;125:859-69 pubmed publisher
Li S, Chen C, Lu H, Huang W, Tien W, Lan Y, et al. Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma. Surgery. 2015;157:570-80 pubmed publisher
Lee H, Park M, Kim M, Kim S, Roh M, Kim K, et al. Overexpression of phosphorylated 4E-binding protein 1 and its clinicopathological significances in gastric cancer. Pathol Res Pract. 2015;211:298-302 pubmed publisher
Haddad A, Kapur P, Singla N, Raman J, Then M, Nuhn P, et al. Validation of mammalian target of rapamycin biomarker panel in patients with clear cell renal cell carcinoma. Cancer. 2015;121:43-50 pubmed publisher
Weisberg E, Nonami A, Chen Z, Nelson E, Chen Y, Liu F, et al. Upregulation of IGF1R by mutant RAS in leukemia and potentiation of RAS signaling inhibitors by small-molecule inhibition of IGF1R. Clin Cancer Res. 2014;20:5483-95 pubmed publisher
Smith H, Matthews K, Oldham J, Jeanplong F, Falconer S, Bass J, et al. Translational signalling, atrogenic and myogenic gene expression during unloading and reloading of skeletal muscle in myostatin-deficient mice. PLoS ONE. 2014;9:e94356 pubmed publisher
Fang Z, Lu L, Tian Z, Luo K. Overexpression of phosphorylated 4E-binding protein 1 predicts lymph node metastasis and poor prognosis of Chinese patients with hilar cholangiocarcinoma. Med Oncol. 2014;31:940 pubmed publisher
Wu J, Shin J, Xie D, Wang H, Gao J, Zhong X. Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. J Immunol. 2014;192:2643-50 pubmed publisher
López Rivera E, Jayaraman P, Parikh F, Davies M, Ekmekcioglu S, Izadmehr S, et al. Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2. Cancer Res. 2014;74:1067-78 pubmed publisher
Rojo F, Domingo L, Sala M, Zazo S, Chamizo C, Menendez S, et al. Gene expression profiling in true interval breast cancer reveals overactivation of the mTOR signaling pathway. Cancer Epidemiol Biomarkers Prev. 2014;23:288-99 pubmed publisher
Badescu A, Couvelard A, Handra Luca A. Akt pathway protein expression in gastrointestinal Kaposi sarcomas: relevance for tumor biology. APMIS. 2014;122:518-25 pubmed publisher
Levidou G, Siakantaris M, Papadaki T, Papadavid E, Vassilakopoulos T, Angelopoulou M, et al. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides. J Am Acad Dermatol. 2013;69:375-84 pubmed publisher
Korkolopoulou P, Levidou G, Trigka E, Prekete N, Karlou M, Thymara I, et al. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma. BJU Int. 2012;110:E1237-48 pubmed publisher
Trancikova A, Mamais A, Webber P, Stafa K, Tsika E, Glauser L, et al. Phosphorylation of 4E-BP1 in the mammalian brain is not altered by LRRK2 expression or pathogenic mutations. PLoS ONE. 2012;7:e47784 pubmed publisher
Murai A, Asa S, Kodama A, Hirata A, Yanai T, Sakai H. Constitutive phosphorylation of the mTORC2/Akt/4E-BP1 pathway in newly derived canine hemangiosarcoma cell lines. BMC Vet Res. 2012;8:128 pubmed publisher
Murai A, Abou Asa S, Kodama A, Sakai H, Hirata A, Yanai T. Immunohistochemical analysis of the Akt/mTOR/4E-BP1 signalling pathway in canine haemangiomas and haemangiosarcomas. J Comp Pathol. 2012;147:430-40 pubmed publisher
Yoon D, Ryu M, Park Y, Lee H, Lee C, Ryoo B, et al. Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum. Br J Cancer. 2012;106:1039-44 pubmed publisher
Xing H, Yang X, Liu T, Lin J, Chen X, Gong Y. The study of resistant mechanisms and reversal in an imatinib resistant Ph+ acute lymphoblastic leukemia cell line. Leuk Res. 2012;36:509-13 pubmed publisher
Tambe Y, Okuyama N, Nakagawa T, Muramoto A, Hasebe M, Chano T, et al. Suppression of viral replication by drs tumor suppressor via mTOR dependent pathway. Cancer Lett. 2012;314:82-91 pubmed publisher
Lee D, Do I, Choi K, Sung C, Jang K, Choi D, et al. The expression of phospho-AKT1 and phospho-MTOR is associated with a favorable prognosis independent of PTEN expression in intrahepatic cholangiocarcinomas. Mod Pathol. 2012;25:131-9 pubmed publisher
product information
SKU :
2846S
Product-Name :
Phospho-4E-BP1 (Thr37/46) (236B4) Rabbit mAb (Alexa Fluor® 488 Conjugate)
Size :
100 ul
Price-(USD) :
291 USD
Species-x-Reactivity :
H, M, R, Mk
Applications :
Flow cytometry
Product-Category :
Translational Control
Shipping-Temp :
COLD
Storage-Temp :
4°C
Product-Type :
Monoclonal Antibody
Host :
Rabbit
Target :
4E-BP1 (Thr37/Thr46) phosphate
Primary-Protein :
4E-BP1
Alt-Names :
4E-BP1,4EBP1,BP-1,EIF4EBP1,Eukaryotic translation initiation factor 4E-binding protein 1,MGC4316,PHAS-I,Phosphorylated heat- and acid-stable protein regulated by insulin 1,eIF4E-binding protein 1,eukaryotic translation initiation factor 4E binding protein 1
more info or order :
Cell Signaling Technology product webpage
company information
Cell Signaling Technology
3 Trask Lane
Danvers, MA 01923
info@cellsignal.com
www.cellsignal.com
8776162355
headquarters: USA
Established in Beverly, MA in 1999, Cell Signaling Technology (CST) is a privately-owned company with over 400 employees worldwide. We are dedicated to providing innovative research tools that are used to help define mechanisms underlying cell function and disease. Since its inception, CST has become the world leader in the production of the highest quality activation-state and total protein antibodies utilized to expand knowledge of cell signaling pathways. Our mission is to deliver the world's highest quality research tools that accelerate progress in biological research and personalized medicine.